Published • loading... • Updated
Orphan Medicinal Product for Spinal Cord Injury Studied in Paraplegics
Summary by clm24.es
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
The European Commission has granted the designation of orphan medicine to rimonabant (SFT-1), a drug for spinal cord injuries in whose clinical research the National Hospital of Paraplegics of Toledo participates. The study seeks to improve the march of people with incomplete spinal injury who retain the ability to walk. The designation promotes the development of the drug, but does not yet authorize its marketing nor shows by itself that it is …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
